BMP inhibitors and the study of disease mechanisms in anemia of inflammation
BMP inhibitors and the study of disease mechanisms in anemia of inflammation
批准号:
7921440
负责人:
KENNETH D BLOCH
金额:
$49.85万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2013-06-30
关键词:
AdolescentAnemiaAnemia due to Chronic DisorderAutoimmune DiseasesBindingBiologicalBiological ProcessBloodBlood CirculationBone MarrowBone Morphogenetic ProteinsChemicalsChronically IllDevelopmentDiagnosisDietary IronDiseaseDuodenumEmbryoEquilibriumErythrocytesErythropoiesisErythropoietinHemochromatosisHemoglobinHepaticHepatocyteHomeostasisInflammatoryInterleukin-6IronIron OverloadKidney DiseasesLeadLigandsLinkLongevityMalignant NeoplasmsMammalian CellModelingMorbidity - disease rateMusPathogenesisPathway interactionsPatientsPharmaceutical ChemistryPhosphotransferasesPlasmaPrincipal InvestigatorProductionProtein FamilyProtein InhibitionRNA InterferenceReportingResearchResearch PersonnelResearch Project GrantsRoleScreening procedureSerum iron level resultSignal TransductionSmall Molecule Chemical LibrarySpecificityTestingTherapeuticVertebratesZebrafishabsorptionbasebone morphogenetic protein receptor type Ibone morphogenetic protein receptorsclinical applicationcytokinedesigndisease mechanisms studyefficacy testinghepcidinhuman diseasein vivoinhibitor/antagonistinsightknock-downloss of function mutationmacrophagemetal transporting protein 1mortalitymouse modelnovel therapeuticspeptide hormonepreventprogramspublic health relevancereceptorsmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Anemia of inflammation (AI) is a frequent contributor to the morbidity associated with cancer, kidney disease, and autoimmune diseases. AI is most often caused by an increased expression of inflammatory cytokines leading to maladaptive over-expression of hepcidin, a peptide hormone and critical regulator of systemic iron balance. Increased hepcidin expression decreases serum levels of iron, reducing its availability for erythropoiesis. Recent evidence has suggested a pivotal role for bone morphogenetic proteins (BMPs) in regulating hepcidin expression, raising the possibility that BMP antagonists could be used for treating AI. Utilizing a unique in vivo screening approach, the principal investigators have identified dorsomorphin and its derivatives as the first small molecule inhibitors of BMP signaling. Collaborative studies using zebrafish and mice have shown that these BMP pathway inhibitors can reduce hepcidin expression and boost serum iron levels in vivo, further supporting the potential of these small molecules for treating AI. This project seeks to understand the mechanisms by which BMP signals contribute to AI and to develop BMP antagonists for treating AI. The following Specific Aims will be pursued: AIM 1: To identify the BMP receptors and ligands that are required for the induction of hepcidin expression by inflammatory cytokines. BMP ligands and receptors will be knocked down in cultured hepatocytes using RNAi and Cre/lox approaches. Complementary in vivo studies will be performed in zebrafish using morpholinos. AIM 2: To optimize dorsomorphin derivatives using medicinal chemistry. Small molecule BMP inhibitors will be developed with enhanced selectivity and receptor-subtype specificity. AIM 3: To test the efficacy of small molecule BMP antagonists in mammalian models of the anemia of inflammation. The ability of dorsomorphin derivatives to increase iron and hemoglobin concentrations will be tested in mouse models of AI. Completion of this project will clarify the mechanisms by which BMP signals contribute to the development of AI and validate BMP pathway antagonism as a therapeutic approach for AI. PUBLIC HEALTH RELEVANCE: Anemia of Inflammation, a blood condition afflicting a third of all chronically-ill patients, has been linked to unwanted activation of a family of proteins called BMP receptors. Recently, chemical compounds that specifically block activation of BMP receptors have been discovered. This research project seeks to optimize and test these BMP receptor blockers for treating Anemia of Inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving Outcomes in Cardiac Arrest/CPR with Inhaled Nitric Oxide
-
批准号:8449637
-
项目类别:
-
资助金额:$47.8万
-
财政年份:2012
-
负责人:KENNETH D BLOCH
-
依托单位:
Improving Outcomes in Cardiac Arrest/CPR with Inhaled Nitric Oxide
-
批准号:8312075
-
项目类别:
-
资助金额:$50.88万
-
财政年份:2012
-
负责人:KENNETH D BLOCH
-
依托单位:
Improving Outcomes in Cardiac Arrest/CPR with Inhaled Nitric Oxide
-
批准号:8645720
-
项目类别:
-
资助金额:$51.5万
-
财政年份:2012
-
负责人:KENNETH D BLOCH
-
依托单位:
BMP inhibitors and the study of disease mechanisms in anemia of inflammation
-
批准号:7676519
-
项目类别:
-
资助金额:$48.62万
-
财政年份:2009
-
负责人:KENNETH D BLOCH
-
依托单位:
BMP inhibitors and the study of disease mechanisms in anemia of inflammation
-
批准号:8131265
-
项目类别:
-
资助金额:$7.39万
-
财政年份:2009
-
负责人:KENNETH D BLOCH
-
依托单位:
BMP inhibitors and the study of disease mechanisms in anemia of inflammation
-
批准号:8109909
-
项目类别:
-
资助金额:$45.87万
-
财政年份:2009
-
负责人:KENNETH D BLOCH
-
依托单位:
BMP inhibitors and the study of disease mechanisms in anemia of inflammation
-
批准号:8303002
-
项目类别:
-
资助金额:$45.43万
-
财政年份:2009
-
负责人:KENNETH D BLOCH
-
依托单位:
Nitric oxide synthase 3 and left ventricular remodeling
-
批准号:6612065
-
项目类别:
-
资助金额:$42.89万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:6765259
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:7237194
-
项目类别:
-
资助金额:$39.11万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:7526759
-
项目类别:
-
资助金额:$41.68万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:7081277
-
项目类别:
-
资助金额:$40.28万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
Nitric oxide synthase 3 and left ventricular remodeling
-
批准号:6882666
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:6904432
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:7660405
-
项目类别:
-
资助金额:$41.89万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:8112654
-
项目类别:
-
资助金额:$41.94万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:6677555
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
Nitric oxide synthase 3 and left ventricular remodeling
-
批准号:7058856
-
项目类别:
-
资助金额:$40.1万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
BMPR2 and the Pathogenesis of Pulmonary Hypertension
-
批准号:7898588
-
项目类别:
-
资助金额:$41.94万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
Nitric oxide synthase 3 and left ventricular remodeling
-
批准号:6765118
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2003
-
负责人:KENNETH D BLOCH
-
依托单位:
国内基金
海外基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
-
批准号:82302715
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:熊泽康
-
依托单位:
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:陈英伟
-
依托单位:
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
-
批准号:31200592
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:孙伟力
-
依托单位: